# Genetic Ablation of CD33 in HSC to Broaden the Therapeutic Index of CD33-directed Immunotherapy in Patients with AML

> **NCT05662904** · PHASE1 · NOT_YET_RECRUITING · sponsor: **German Cancer Research Center** · enrollment: 12 (estimated)

## Conditions studied

- Relapsed/Refractory Acute Myeloid Leukemia (AML)

## Interventions

- **BIOLOGICAL:** Donor-derived CD34+ HSC with CRISPR/Cas9-mediated CD33 deletion
- **DRUG:** Gemtuzumab Ozogamicin

## Key facts

- **NCT ID:** NCT05662904
- **Lead sponsor:** German Cancer Research Center
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2028-01
- **Primary completion:** 2029-01
- **Final completion:** 2030-01
- **Target enrollment:** 12 (ESTIMATED)
- **Last updated:** 2025-03-14

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05662904

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05662904, "Genetic Ablation of CD33 in HSC to Broaden the Therapeutic Index of CD33-directed Immunotherapy in Patients with AML". Retrieved via AI Analytics 2026-06-26 from https://api.ai-analytics.org/clinical/NCT05662904. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*